Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 225
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S551F1D44FDEN
Leaflet:

Download PDF Leaflet

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 14, 5, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Systemic Sclerosis (Scleroderma) - Overview
Systemic Sclerosis (Scleroderma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
Allergan Plc
AnaMar AB
Angion Biomedica Corp
arGentis Pharmaceuticals LLC
Bayer AG
Biogen Inc
BLR Bio LLC
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Covis Pharmaceuticals Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Fibrocell Science Inc
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
iBio Inc
Inventiva
Leadiant Biosciences Inc
MedImmune LLC
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals LLC
Peptinov SAS
ProMetic Life Sciences Inc
Ribomic Inc
Samumed LLC
Sanofi
Seattle Genetics Inc
Stemline Therapeutics Inc
Stratatech Corp
Vicore Pharma AB
viDA Therapeutics Inc
VivaCell Biotechnology Espana SL
Systemic Sclerosis (Scleroderma) - Drug Profiles
abatacept - Drug Profile
acALY-18 - Drug Profile
ambrisentan - Drug Profile
anabasum - Drug Profile
ANG-3070 - Drug Profile
ARG-201 - Drug Profile
belimumab - Drug Profile
BLR-200 - Drug Profile
brentuximab vedotin - Drug Profile
C-1889 - Drug Profile
C-21 - Drug Profile
C-82 - Drug Profile
Cell Therapy for Dermatology and Immunology - Drug Profile
CM-101 - Drug Profile
dimethyl fumarate DR - Drug Profile
elapegademase - Drug Profile
factor XIII (human) - Drug Profile
FCX-013 - Drug Profile
GKT-831 - Drug Profile
GSK-2330811 - Drug Profile
IBIOCFB-03 - Drug Profile
ifetroban sodium - Drug Profile
IVA-337 - Drug Profile
M-10 - Drug Profile
MEDI-7734 - Drug Profile
miRNA-29 - Drug Profile
Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile
nintedanib - Drug Profile
nitroglycerin - Drug Profile
onabotulinumtoxinA - Drug Profile
PAT-048 - Drug Profile
PATS-03 - Drug Profile
PBI-4050 - Drug Profile
PBI-4425 - Drug Profile
PDX-002 - Drug Profile
PPV-06 - Drug Profile
RBM-006 - Drug Profile
riociguat - Drug Profile
rituximab biosimilar - Drug Profile
RP-182 - Drug Profile
SAR-100842 - Drug Profile
SAR-156597 - Drug Profile
SAR-317461 - Drug Profile
SM-04755 - Drug Profile
Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile
Small Molecules to Antagonize 5-HT2B for Idiopathic Pulmonary Fibrosis and Systemic Sclerosis - Drug Profile
sodium nitrite SR - Drug Profile
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile
terguride - Drug Profile
tocilizumab - Drug Profile
TRX-101 - Drug Profile
VCE-0048 - Drug Profile
VEDA-1209 - Drug Profile
VTI-1000 Series - Drug Profile
Wnt-001 - Drug Profile
Systemic Sclerosis (Scleroderma) - Dormant Projects
Systemic Sclerosis (Scleroderma) - Discontinued Products
Systemic Sclerosis (Scleroderma) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by BLR Bio LLC, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune LLC, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Seattle Genetics Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corp, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by viDA Therapeutics Inc, H2 2017
Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana SL, H2 2017
Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017
Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017 (Contd..1), H2 2017
Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Ask Your Question

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: